A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Clinical trial NCT00220194 · COMPLETED
Trial details
- NCT number
- NCT00220194
- Sponsor
- San Bernardino Urological Associates Medical Group Inc
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2003-04-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.